Bosh sahifa500660 • BOM
add
GlaxoSmithKline Pharmaceuticals Ltd
Yopilish kursi
2 043,35 ₹
Kunlik diapazon
2 029,90 ₹ - 2 066,80 ₹
Yillik diapazon
1 825,05 ₹ - 3 087,95 ₹
Bozor kapitalizatsiyasi
343,89 mlrd INR
Oʻrtacha hajm
2,91 ming
Narx/foyda
51,26
Dividend daromadliligi
1,58%
Asosiy maydon
NSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (INR) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 10,11 mlrd | 5,62% |
Joriy xarajat | 3,21 mlrd | -2,94% |
Sof foyda | 2,52 mlrd | 16,09% |
Sof foyda marjasi | 24,98 | 9,90% |
Har bir ulushga tushum | — | — |
EBITDA | 3,21 mlrd | 11,39% |
Amaldagi soliq stavkasi | 26,56% | — |
Balans
Jami aktivlari
Jami passivlari
| (INR) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 21,11 mlrd | 31,49% |
Jami aktivlari | 37,46 mlrd | 14,55% |
Jami passivlari | 20,73 mlrd | 19,80% |
Umumiy kapital | 16,73 mlrd | — |
Tarqatilgan aksiyalar | 172,12 mln | — |
Narxi/balansdagi bahosi | 21,03 | — |
Aktivlardan daromad | — | — |
Kapitaldan daromad | 43,75% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (INR) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 2,52 mlrd | 16,09% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
Tashkil etilgan
13-noy, 1924
Xodimlar soni
3 211
